“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in SEK
Last close As at 02/06/2023
SEK1.49
▲ 0.04 (2.76%)
Market capitalisation
SEK59m
Scandion Oncology is focused on the development of add-on therapies to reverse chemotherapy resistance in oncology. Lead asset SCO-101 is in a Phase II trial for metastatic colorectal cancer (mCRC) and a Phase Ib trial for pancreatic cancer.
Tumours often develop resistance to chemotherapeutic regimens. Widely available drugs, such as irinotecan and paclitaxel, are commonly associated with tumour resistance. The existence of add-on therapies to reverse resistance of this type will be an attractive prospect to many clinicians, in our view.
Managing Director - Head of Content, Healthcare
Francois Martelet
CEO
Johnny Stilou
CFO
Mads Kronborg
Head of external communication
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (15.6) | (28.5) | (89.3) |
| Relative | (12.8) | (26.7) | (89.3) |
| 52 week high/low | SEK9.3/SEK1.4 |
Scandion Oncology is a biotechnology company focused on the development of add-on therapies to reverse chemotherapy resistance in oncology. Lead asset SCO-101 is currently in a Phase II trial for mCRC and a Phase Ib trial for pancreatic cancer. In H222 management undertook a rights issue, raising c SEK75m gross, mainly to fund the expansion of the SCO-101 clinical development programme to include patients harbouring RAS mutations. As such, part 3 of the CORIST trial in mCRC is currently recruiting. While top-line readouts from the CORIST part 2 mCRC trial did not achieve the primary endpoint for efficacy, patients are continuing treatment and longer-term efficacy benefits may be realised. In December 2022, Francois Martelet was appointed CEO of Scandion. We estimate that Scandion is funded into FY24. We value the company at SEK238.2m or SEK5.8/share.
| Y/E Dec | Revenue (DKKm) | EBITDA (DKKm) | PBT (DKKm) | EPS (ore) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2021A | 0.8 | (54.8) | (57.2) | (161.0) | N/A | N/A |
| 2022A | 2.1 | (79.3) | (82.2) | (187.0) | N/A | N/A |
| 2023E | 0.6 | (65.3) | (65.3) | (147.0) | N/A | N/A |
| 2024E | 0.6 | (69.0) | (69.4) | (157.0) | N/A | N/A |
Get access to the very latest content matched to your personal investment style.
